Investor Presentation • Mar 23, 2022
Investor Presentation
Open in ViewerOpens in native device viewer

London, Cambridge & Oxford
Sean Coghlan | Global Head of Capital Markets Research, JLL 23rd March 2022

© 2022 Jones Lang LaSalle IP, Inc. All rights reserved.


Access to highly skilled workforce






Diminishing stimulus will set growth rates back on the path toward their natural rates

As stimulus fades postpandemic, GDP growth rates are slowing toward trend rates

The Ukraine crisis will cause growth rates to soften, but still remain positive
Inflation is likely to be higher and for longer, amplified by the crisis

Office employment expected to recover in 2022 (growing 2.2%) 0.0



| Office take-up by market | Central London at a glance | ||||
|---|---|---|---|---|---|
| 14 12 |
2021 | 10-year average |
|||
| 10 | Quarterly take-up (sq ft) Annual take-up (sq ft) |
8.5 million | 2.5 million 10.0 million |
||
| 8 q ft |
Under offer (sq ft) |
2.9 million | 2.5 million | ||
| s n 6 o Milli |
+80% | Active demand (sq ft) |
8.3 million | 8.8 million | |
| 4 | Overall vacancy | 7.6% | 5.1% | ||
| 2 | New build vacancy | 1.7% | 1.1% | ||
| 0 | Speculative under construction (sq ft) |
9.6 million | 7.5 million | ||
| 2011 2012 2013 2014 2015 2016 2017 City West End East London |
2018 2019 2020 2021 10- year average |
Quarterly Investment volumes Annual Investment volumes |
£13.7 billion | £3.8 billion £15.0 billion |


Significant footprint growth by big tech

King's Cross / Covent Garden / Victoria
800,000 sq ft | New c1.0m sq ft HQ underway in King's Cross

Shoreditch / Midtown
825,000 sq ft

Noho / King's Cross / Euston
1.6 million sq ft

Battersea / City / Regent Street
270,000 sq ft | Pre-let 500,000 sq ft in Battersea for new HQ


Bridge & Waterloo stations


© 2022 Jones Lang LaSalle IP, Inc. All rights reserved. 7 Source : JLL Research


9.6 million sq ft Under construction speculatively
50% Located in the City

2021 completions totalled 4.6 million sq ft 45% was pre-let / owner occupied

2022 total space under construction
41% 3.2m sq ft (pre-let) 6% 0.4m sq ft (under offer) 53% 4.1m sq ft (speculative)





Source : JLL Research
© 2022 Jones Lang LaSalle IP, Inc. All rights reserved. 10


Life Sciences in the Golden Triangle
© 2022 Jones Lang LaSalle IP, Inc. All rights reserved. 12

| Life Sciences is a critical part of Knowledge Intensive Industries that includes Tech and High-Tech Manufacturing The Office for Life Sciences (OLS), a UK central government body defines Life Sciences as 'the application of biology and technology to health improvement' |
Diverse sector with multiple subsectors |
Important to understand growth characteristics and facility needs |
|
|---|---|---|---|
| Sub sectors | Who (examples) | Needing | |
| Pharma, Therapeutics & diagnostics | Offices Wet labs (high & low spec) Dry labs | ||
| R&D Service - Discovery & development |
Wet labs (high & low spec) | ||
| Medtech | Dry labs Offices | ||
| Pharmatech & Healthtech |
Offices |

A range of non real estate data points provide insight on current and future trends that will underpin real estate performance across different geographies and clusters


Total Venture Capital Investment to UK Life Science Companies (£Bn)


| Advanced: | Cluster | USP | Company Numbers |
Employment | VC Investment (£M) |
Leading Universities |
High Quality Publications |
||
|---|---|---|---|---|---|---|---|---|---|
| Oxford, Cambridge, London |
London | Digital Health |
|||||||
| Established: | Cambridge | Antibody/Advanced Therapeutics & AI |
|||||||
| Stevenage, Manchester, Edinburgh, Glasgow, |
Oxford | Therapeutics & Regenative Medicine |
|||||||
| Edinburgh Glasgow |
Nottingham | Stevenage | Cell Therapy & Gene |
||||||
| Emerging: | Edinburgh | MedTech & Genetics |
|||||||
| Newcastle | Birmingham, Newcastle, Leeds, |
Manchester | Advanced Materials |
||||||
| Cardiff | Glasgow | Medicine Precision & AgTech |
|||||||
| Leeds Manchester |
Birmingham | Medical Technology |
|||||||
| Nottingham | Newcastle | Ageing | |||||||
| Birmingham | Cambridge Stevenage |
Nottingham | Pharmacology , Chemistry , Regen Medicine |
||||||
| Oxford | London | Leeds | Digital Health |

| Cambridge | Oxford | London (Kings Cross) |
|||||
|---|---|---|---|---|---|---|---|
| Occupational / Investor Metrics – Life Sciences |
|||||||
| ERV growth pa 2015-20 | 6.00% | 10.00% | 1.00% | ||||
| Forecasted ERV growth | 2.50% | 3.00% | 3.00% | ||||
| Prime Life Science yield NIY (2015) |
6.00% | 5.75% | 3.50% | ||||
| Prime Life Science yield NIY (2021) |
4.00% | 4.00% | 3.50% | ||||
| Trending | Stronger | Stronger | Stable | ||||
| Life Science Cap Rate premium* |
- 75 BPS |
- 75 BPS |
- 25 to 50 BPS |
||||
| Prime Office Rent (psf) | £37.50 | £37.50 | £82.50 | ||||
| Prime Lab Rent (psf) | £50.00 + | £50.00 + | £100.00 + | ||||
| Rent premium (%)** | 33.00% + | 33.00% + | 20.00% + |
* Life Sciences cap rate premium over prime offices
** Life Sciences rental premium over prime offices



© 2022 Jones Lang LaSalle IP, Inc. All rights reserved. The information contained in this document is proprietary to Jones Lang LaSalle and shall be used solely for the purposes of evaluating this proposal. All such documentation and information remains the property of Jones Lang LaSalle and shall be kept confidential. Reproduction of any part of this document is authorized only to the extent necessary for its evaluation. It is not to be shown to any third party without the prior written authorization of Jones Lang LaSalle. All information contained herein is from sources deemed reliable; however, no representation or warranty is made as to the accuracy thereof.

Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.